CAMBRIDGE, MA--(Marketwire - June 22, 2012) -
| Highlighted Links |
|
Radius Health, a development-stage biopharmaceutical company focused on advanced therapies for healthy aging, will present scientific data from studies conducted with BA058 (a product candidate currently being developed for the treatment of postmenopausal osteoporosis) at ENDO 2012: The Endocrine Society’s 94th Annual Meeting and Expo, Houston, June 23-26, 2012.
The data will be presented in two oral presentations:
OR08-1 - Bone Anabolic Efficacy and Safety of BA058, a Novel Analog of hPTHrP: Results from a Phase 2 Clinical Trial in Postmenopausal Women with Osteoporosis
Session Name: Osteoporosis Physiology & Clinical Trials
Date: Saturday, June 23, 2012
Time: 11:15 AM
Room: Theater A, George R Brown Convention Center
OR13-6 - BA058, a Novel hPTHrP Analog, Reverses Bone Loss and Improves Bone Strength in Ovariectomized Rats
Session Name: Osteoblasts & Bone Biology
Date: Sunday, June 24, 2012
Time: 11:15 AM
Room: 342ABDE, George R Brown Convention Center
In addition, Radius Health will present data from preclinical studies conducted with RAD140, the company’s lead SARM (selective androgen receptor modulator) product candidate:
SUN-525 - A Selective Androgen Receptor Modulator (RAD140) Induces Inflammation in Rat Right Heart Ventricle: Evidence for an Androgen-Specific, Species-Specific Mechanism
Date: Sunday, June 24, 2012
Time: 1:30 - 3:30 PM
Room: Exposition Hall, George R Brown Convention Center
Poster Board Number: SUN-525
About BA058
BA058 is Radius’ anabolic (bone-building) drug in development for the treatment of postmenopausal osteoporosis. BA058 is an analog of hPTHrP (human parathyroid hormone-related protein) in development by Radius in subcutaneous injection and transdermal delivery forms:
- BA058 Injection is currently in a Phase 3 clinical study. In Phase 1 and 2 studies involving otherwise healthy postmenopausal women, BA058 Injection demonstrated the ability to stimulate bone formation at fracture sites, with limited effect on bone resorption and minimized risk of hypercalcemia.
- The BA058 Microneedle Patch has completed Phase 1 clinical studies. Radius is developing the transdermal form of BA058 based on 3M Drug Delivery Systems’ Solid Microstructured Transdermal Systems (sMTS) microneedle technology platform. In Phase 1 studies, the BA058 Microneedle Patch demonstrated safety and tolerability in otherwise healthy postmenopausal women in all doses studied, with a suitable pharmacokinetic profile.
Radius acquired exclusive worldwide rights (excluding Japan) to develop, manufacture, and distribute BA058 and its analogs from Ipsen in 2005.
About Radius (www.radiuspharm.com)
Radius is a leading development-stage biopharmaceutical company focused on advanced drug therapies for healthy aging. BA058, Radius’ proprietary analog of PTHrP (parathyroid hormone-related protein), is in clinical development as a treatment for postmenopausal osteoporosis in two delivery options: BA058 Injection is a subcutaneous injection form in a Phase 3 clinical study; and the BA058 Microneedle Patch, which has completed Phase 1 evaluation, is a short wear-time, transdermal form based on a microneedle technology from 3M Drug Delivery Systems. The company has a pipeline of additional drug candidate programs in earlier stages of development. Radius is located in Cambridge, Massachusetts.
Safe Harbor for Forward-Looking Statements
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the development of Radius’ products, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Radius or its management, may identify forward-looking statements. Radius cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Radius to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of Radius’ proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that Radius may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Radius’ business, financial conditions and results of operations are contained in Radius’ filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. The forward-looking statements represent Radius’ estimate as of the date hereof only, and Radius specifically disclaims any duty or obligation to update forward-looking statements
